J&J adds yet an­oth­er mul­ti­ple myelo­ma reg­i­men to the Darza­lex la­bel as Sanofi ri­val jumps in

J&J’s third-line mul­ti­ple myelo­ma block­buster Darza­lex got the FDA green light for a new reg­i­men to take an­oth­er swing at the blood can­cer — this time …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.